Crescita Therapeutics (Crescita Therapeutics) GF Score : 38/100 (As of May. 14, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics GF Score?

Crescita Therapeutics has the GF Score of 38, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 4/10
3. Growth Rank : 1/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Crescita Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Crescita Therapeutics's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's GF Score falls into.

Crescita Therapeutics (OTCPK:CRRTF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Crescita Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (Crescita Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.